TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04053140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array and closed-loop control of penicillin delivery
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array and closed-loop control of penicillin delivery
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
Study: NCT02569359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: shea nut oil extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00345163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intravenous repeating dose
Study: NCT02527070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESPeRATE (Paced Breathing)
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE (Paced Breathing)
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum Warp10 (Red LED)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnilux new-U (Near Infrared LED)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat/cold provocation
Description: Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat/cold provocation
Description: Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
Study: NCT01810627

Intervention type: RADIATION
Intervention: MVCT
Description: Patients will receive an additional MVCT scan at their one month follow up visit.
Study: NCT01998594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty
Description: A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
Study: NCT01639105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: 10 600 NM ABLATIEVE FRACTIONATED LASER
Study: NCT03735160

Intervention type: DEVICE
Intervention: pressure sensor
Description: Pressure sensor at the angle of intratracheal tube and nasal alar
Study: NCT04559282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Sound Processor
Description: The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Sound Processor
Description: The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
Study: NCT02176681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (Galvus)
Description: Use Vildagliptin (50 mg/day) added to insulin during 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin
Study: NCT04508296

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Goal directed de-escalation therapy
Description: Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI \> 650 mL/m2 or EVLWI \> 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Goal directed de-escalation therapy
Description: Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI \> 650 mL/m2 or EVLWI \> 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
Study: NCT00965796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2 mg/kg/h- during surgical procedure Saline
Study: NCT03492736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 30 days 10mg Melatonin taken nightly 1 hour before bed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 days placebo taken nightly 1 hour before bed
Study: NCT02980003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. sodium bicarbonate
Description: patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sodium bicarbonate
Description: patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
Study: NCT02749851

Intervention type: DEVICE
Intervention: MRI
Description: Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.

Intervention type: DEVICE
Intervention: MRI
Description: Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.

Intervention type: DEVICE
Intervention: MRI
Description: Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.

Intervention type: DEVICE
Intervention: MRI - IUGR
Description: Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
Study: NCT02784223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation : PET-CT with F18-choline examination
Description: PET-CT with F18-choline examination will be performed before surgery
Study: NCT03395249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR994
Description: SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Orapenem®
Description: Tebipenem pivoxil granules
Study: NCT04394845

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).
Study: NCT01779479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabacitaxel
Description: Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
Study: NCT01381874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane
Description: Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate + Prednisone or Prednisolone
Description: Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
Study: NCT04530539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000mg Vitamin C, at bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 10mg melatonin, at bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom Survey
Description: Daily symptom survey to be completed by patient electronically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: Daily symptom survey to be completed by patient electronically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: Daily symptom survey to be completed by patient electronically
Study: NCT01110343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness intervention
Description: a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional parent Support Group
Description: a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
Study: NCT04114747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starting at high or low blood pressure
Description: Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starting at high or low blood pressure
Description: Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
Study: NCT04232046

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
Study: NCT00452413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally
Study: NCT04053140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_1200mg
Description: Benzylpenicillin IV 1200mg administered every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_2400mg
Description: Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_600mg/hr
Description: Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
Study: NCT03349554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: body-scan meditation
Description: 15 minutes audio-guided body-scan meditation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation
Study: NCT03945370

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-hydroxybuturate esters
Description: Oral dietary supplement product containing β-hydroxybuturate esters

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: β-hydroxybuturate esters
Description: Oral dietary supplement product containing β-hydroxybuturate esters

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drink
Description: Oral placebo drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Oral placebo drink
Study: NCT03425409

Intervention type: DEVICE
Group type: OTHER
Intervention: Integra Pulse Portable- Continuous flow
Description: 4 liters per minute oxygen flow

Intervention type: DEVICE
Group type: OTHER
Intervention: Integra Pulse Portable- Pneumatic pulsed flow
Description: Oxygen flow determined by test device
Study: NCT02729038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
Study: NCT04603768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband exercises
Description: Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise \& Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-contraction exercises
Description: Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright \& contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets \& 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week
Study: NCT00452413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Administered orally
Study: NCT03084497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infant Massage
Description: The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation.
Study: NCT02761889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 45 Gy in 5 fractions of 9 Gy
Description: Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)
Description: Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal balloon with air filling
Description: A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urethral catheter loaded with beacon transponders
Description: A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.